Since its inception in 2022, the Endometrial Cancer Molecularly Targeted Therapy Consortium (ECMT2) has been at the forefront of advancing research in endometrial cancer. Our dedicated investigators continue to share groundbreaking findings at international conferences, bridging science and community to promote transformational change in prevention and care. With a strong focus on biomarker discovery and molecular profiling, ECMT2 strives to improve outcomes and tailor treatments for diverse patient populations.

Entering its seventh year, the consortium has proudly presented multiple award-winning abstracts and numerous research posters, reflecting a rich collaboration of clinicians, fellows, and medical students from leading institutions. Our work not only drives scientific innovation but also fosters community awareness, with impactful studies addressing racial disparities, targeted therapies, and immune response. Together, ECMT2 is committed to paving the way for more effective, personalized therapies and better lives for those affected by endometrial cancer.

Our Fundraising Progress